Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06550427
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-08
Brief Title:
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan Large B-cell lymphoma LBCL is the most common subtype of aggressive B-cell lymphoma LBCLs aggressive nature manifests through extranodal involvement severe symptoms and relative refractoriness to therapies leading to a 5-year overall survival rate of 60-70 across developed countries and poorer outcomes in high-risk patients with primary refractory disease Chemoimmunotherapy remains the primary treatment for LBCL requiring comprehensive assessment through clinical and imaging examinations biomarkers and molecular testing Currently computed tomography CT and positron emission tomography PET scans are the standard modalities for treatment response evaluation though their radioactive nature calls for the development of safer alternatives Circulating tumor DNA ctDNA analysis has emerged as a promising field providing insights into tumor molecular characteristics clinical status and treatment response by analyzing DNA fragments released from tumor cells into the bloodstream Dynamic monitoring of ctDNA during treatment can effectively gauge therapeutic efficacy-decreasing ctDNA concentrations suggest successful treatment while increasing levels may indicate treatment failure or tumor recurrence The detection of ctDNA has been much improved through advances in next-generation sequencing NGS technologies particularly taking advantage of analyzing phased variants consecutive gene mutations on the same chromosome enhances the sensitivity and specificity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None